Protagonist Therapeutics Inc PTGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PTGX is a good fit for your portfolio.
News
-
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
-
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
-
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
-
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
-
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
-
Protagonist Therapeutics Reports Granting of Inducement Awards
-
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
Trading Information
- Previous Close Price
- $24.66
- Day Range
- $24.22–25.23
- 52-Week Range
- $13.72–33.34
- Bid/Ask
- $25.13 / $25.15
- Market Cap
- $1.47 Bil
- Volume/Avg
- 461,248 / 647,028
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 23.79
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 112
- Website
- https://www.protagonist-inc.com
Comparables
Valuation
|
Metric
|
PTGX
|
EQRX
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.31 | 0.97 | 5.69 |
Price/Sales | 23.79 | — | 23.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
PTGX
EQRX
ACLX
Financial Strength
|
Metric
|
PTGX
|
EQRX
|
ACLX
|
|---|---|---|---|
Quick Ratio | 16.54 | 18.43 | 5.94 |
Current Ratio | 16.71 | 18.78 | 6.06 |
Interest Coverage | — | — | −23.39 |
Quick Ratio
PTGX
EQRX
ACLX
Profitability
|
Metric
|
PTGX
|
EQRX
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −16.60% | −15.72% | −6.26% |
Return on Equity (Normalized) | −18.20% | −16.71% | −12.08% |
Return on Invested Capital (Normalized) | −23.45% | −21.31% | −13.11% |
Return on Assets
PTGX
EQRX
ACLX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hgntybpvtf | Qmw | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lsjtbfb | Dmsmwg | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yxzlmjtkd | Jtfrbdb | $97.8 Bil | |
MRNA
| Moderna Inc | Xrhqbgq | Mcgr | $41.3 Bil | |
ARGX
| argenx SE ADR | Bjkzdjy | Stl | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rqlbblstb | Yfvc | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qlmkczt | Hglbblq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zttjyzt | Txkgz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pkxqzscwh | Rslhsb | $12.5 Bil | |
INCY
| Incyte Corp | Fjxydcn | Zzkzg | $11.6 Bil |